Cargando…

SARS-CoV-2 neutralising antibodies in dogs and cats in the United Kingdom

Companion animals are susceptible to SARS-CoV-2 infection and sporadic cases of pet infections have occurred in the United Kingdom. Here we present the first large-scale serological survey of SARS-CoV-2 neutralising antibodies in dogs and cats in the UK. Results are reported for 688 sera (454 canine...

Descripción completa

Detalles Bibliográficos
Autores principales: Smith, Shirley L., Anderson, Enyia R., Cansado-Utrilla, Cintia, Prince, Tessa, Farrell, Sean, Brant, Bethaney, Smyth, Steven, Noble, Peter-John M., Pinchbeck, Gina L., Marshall, Nikki, Roberts, Larry, Hughes, Grant L., Radford, Alan D., Patterson, Edward I.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Authors. Published by Elsevier B.V. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8340563/
https://www.ncbi.nlm.nih.gov/pubmed/34377997
http://dx.doi.org/10.1016/j.crviro.2021.100011
Descripción
Sumario:Companion animals are susceptible to SARS-CoV-2 infection and sporadic cases of pet infections have occurred in the United Kingdom. Here we present the first large-scale serological survey of SARS-CoV-2 neutralising antibodies in dogs and cats in the UK. Results are reported for 688 sera (454 canine, 234 feline) collected by a large veterinary diagnostic laboratory for routine haematology during three time periods; pre-COVID-19 (January 2020), during the first wave of UK human infections (April–May 2020) and during the second wave of UK human infections (September 2020–February 2021). Both pre-COVID-19 sera and those from the first wave tested negative. However, in sera collected during the second wave, 1.4% (n ​= ​4) of dogs and 2.2% (n ​= ​2) of cats tested positive for neutralising antibodies. The low numbers of animals testing positive suggests pet animals are unlikely to be a major reservoir for human infection in the UK. However, continued surveillance of in-contact susceptible animals should be performed as part of ongoing population health surveillance initiatives.